Search Results - "Domínguez Barahona, A"

4CPS-393 Impact of multidisciplinary team intervention in medication reconciliation for geriatric patients by Gonzalez Suarez, S, Martínez Camacho, M, Rodríguez Jímenez, E, Martín Braojos, S, Alfaro Acha, A, Uceta Espinosa, MI, Salguero Olid, A, García Marco, D, Domínguez Barahona, A

“…Background and importanceRecords of prescribed medication in the primary care setting have a high level of discrepancies regarding the medication that…”
Get full text

4CPS-092 Statistical relationship between biomarkers with prognostic value in anti-PDL1 treatments in cancer patients by Toledo Davia, MA, Labrador Andujar, N, Rubio Salvador, AR, Blazquez Romero, C, Torralba Fernandez, L, Jimenez Mendez, C, Prieto Galindo, R, Dominguez Barahona, A, Aguado Barroso, P, Gomez Fernandez, E, Moya Gomez, P

“…Background and ImportanceThe prognostic value of biomarkers such as neutrophil/lymphocyte ratio (NLR), derived neutrophil/lymphocyte ratio (dNLR) and…”
Get full text

4CPS-036 Is our protocol for the use of tocilizumab in COVID patients adequate? by Dominguez Barahona, A, Gonzalez Suárez, S, Toledo Davia, MA, Blazquez Romero, C, Torralba Fernandez, L, Lopez Alvarez, R, Jimenez Mendez, C, Moya Gomez, P

“…Background and importanceTocilizumab (TCZ) has been a key pillar in the management of pulmonary hyperinflammation in patients with SARS-CoV-2 pneumonia. The…”
Get full text

5PSQ-002 Hypomagnesaemia alert! Monitor closely proton pump inhibitors for chronic treatment in elderly patients by Dominguez Barahona, A, Gonzalez Suarez, S, Martinez Camacho, M, Rodriguez Jimenez, E, Alonso Seco, M, Santos Azorín, A, López Álvarez, R, Toledo Davia, MA, García Marco, D

“…Background and importanceThere have only been 175 cases of hypomagnesaemia associated with prolonged use of proton pump inhibitors (PPIs) reported to FEDRA…”
Get full text

4CPS-054 Use of antimicrobial agents in the emergency department in a third-level hospital by Gonzalez Suarez, S, Blázquez Romero, C, Quirós Ambel, H, García Sacristan, AA, Dominguez Barahona, A, López Álvarez, R, Rubio Salvador, AR, Moya Gómez, P

“…BackgroundInfectious diseases are one of the most frequent reasons for consultation in the Emergency Department (ED), as well as one of the main causes of…”
Get full text

4CPS-133 Daratumumab (darzalex) for the treatment of multiple myeloma in a third-level hospital: variability of use and effectiveness by Gonzalez Suarez, S, Rubio Salvador, AR, García Sacristán, AA, Dominguez Barahona, A, López Álvarez, R, Blázquez Romero, C, Labrador Andújar, N, Moya Gómez, P

“…BackgroundDaratumumab is a human monoclonal antibody that binds to CD38 protein, expressed in a high level in the tumour cells of multiple myeloma (MM),…”
Get full text

4CPS-088 Direct-acting antivirals for the treatment of hepatitis c virus infection: a real-world data analysis by Sacristan, A Garcia, Martínez-Sesmero, JM, Ambel, H Quirós, Lista, FJ Manzano, Barahona, A Dominguez, Suarez, S Gonzalez, Gómez, P Moya

“…BackgroundThe use of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) patients has been a controversial issue over the past years in medicine. It has…”
Get full text

4CPS-034 Effectiveness and safety of monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (pcsk9 inhibitors) for the treatment of hypercholesterolaemia by Ambel, H Quiros, Rengifo, C Donoso, Sacristán, AA García, Sesmero, JM Martinez, Barahona, A Dominguez, Suarez, S González, Gomez, P Moya, Romero, C Blazquez

“…BackgroundAlirocumab and evolocumab (PCSK9-Inhibitors), are new drugs incorporated into the therapeutic arsenal for the treatment of hypercholesterolaemia,…”
Get full text

5PSQ-076 Patient-reported outcomes in multiple sclerosis by Sacristan, A Garcia, Sánchez, P López, Sesmero, JM Martínez, Ambel, H Quiros, Barahona, A Dominguez, Suarez, S Gonzalez, Gomez, P Moya

“…BackgroundMultiple sclerosis (MS) is a chronic neurological disease that carries important personal, social and economic consequences for patients and their…”
Get full text

DI-027 Analysis of the durability of antiretroviral monotherapy in hiv infected patients by Ambel, H Quirós, Sesmero, JM Martinez, Sacristán, AA García, Lista, FJ Manzano, Andujar, N Labrador, Barahona, A Dominguez, Romero, C Blazquez, Gomez, P Moya

“…BackgroundOne of the main objectives in the adequacy of HIV antiretroviral treatment is to find the drug or set of drugs that allow the best results to be…”
Get full text